Our experimental results demonstrate that pretreatment of cancer cells with Sorafenib reverses DHA-induced suppression of nuclear Bach1 expression and attenuate DHA-induced HO-1 gene transcription, resulting in a synergistic action that suppresses cancer cell viability and tumor growth. Here, BACH1 is linked to cancer.